{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Ingredient+Group&page=2",
    "query": {
      "intervention": "Control Ingredient Group",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Ingredient+Group&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T01:58:53.718Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06063330",
      "title": "Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "Infectious Disease",
        "Symptomatic COVID-19 Infection Laboratory-Confirmed",
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "RQ-001",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Red Queen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 66,
      "start_date": "2023-09-27",
      "completion_date": "2024-01-03",
      "has_results": false,
      "last_update_posted_date": "2024-01-11",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06063330"
    },
    {
      "nct_id": "NCT03742037",
      "title": "Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Cenerimod 0.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Cenerimod 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Cenerimod 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Cenerimod 4 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "cenerimod 2 mg (ex-4 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 427,
      "start_date": "2018-12-21",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 29,
      "location_summary": "Anniston, Alabama • La Jolla, California • Los Alamitos, California + 25 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742037"
    },
    {
      "nct_id": "NCT02681094",
      "title": "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Inadequate Glycaemic Control"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 905,
      "start_date": "2016-02-26",
      "completion_date": "2017-07-15",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 48,
      "location_summary": "Saraland, Alabama • Fresno, California • Harbor City, California + 41 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        },
        {
          "city": "Hawaiian Gardens",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02681094"
    },
    {
      "nct_id": "NCT04811339",
      "title": "Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diarrhea",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet without BSS",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-10-27",
      "completion_date": "2021-08-15",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04811339"
    },
    {
      "nct_id": "NCT00843466",
      "title": "Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hand Dermatosis"
      ],
      "interventions": [
        {
          "name": "Mild, moisturizing hand cleanser",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2007-05",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00843466"
    },
    {
      "nct_id": "NCT04730193",
      "title": "Caffeine and Cerebrovascular Reactivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Caffeine"
      ],
      "interventions": [
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-01",
      "completion_date": "2022-08-01",
      "has_results": false,
      "last_update_posted_date": "2022-08-09",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730193"
    },
    {
      "nct_id": "NCT05648500",
      "title": "A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Cenerimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 470,
      "start_date": "2022-12-13",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 22,
      "location_summary": "Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05648500"
    },
    {
      "nct_id": "NCT06881888",
      "title": "Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Octreotide (drug)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-08-31",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06881888"
    },
    {
      "nct_id": "NCT03940950",
      "title": "Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteo Arthritis Knee",
        "Degenerative Joint Disease of Knee"
      ],
      "interventions": [
        {
          "name": "Autologous Adipose-Derived SVF (Stromal Vascular Fraction)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-07-02",
      "completion_date": "2025-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03940950"
    },
    {
      "nct_id": "NCT01228513",
      "title": "Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ZK245186",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle without active ingredient)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 263,
      "start_date": "2010-11",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2016-01-21",
      "last_synced_at": "2026-09-13T01:58:53.718Z",
      "location_count": 13,
      "location_summary": "Anaheim, California • Honolulu, Hawaii • Boise, Idaho + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01228513"
    }
  ]
}